Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot study of deferasirox biomarker predictors in myelodysplastic syndrome
2015-003775-30Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in myelodysplastic syndrome (MDS), sponsored by Novartis. Primary endpoint: Differentially expressed genes in responders versus non-responders. Started Nov 2015; status: terminated.
02
Drugs
deferasirox
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2015-003775-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003775-30.